CinFina Pharma: FDA Approves CIN-110 IND for Obesity Treatment, Initiating Phase 1 Study with First Doses Administered

CIN-110, a derivative of peptide YY (PYY3-36), is a long-lasting molecule with the aim of increasing satiety and reducing appetite, as well as influencing glucose metabolism. It is being developed by CinFina Pharma, a company within the CinRx portfolio that focuses on treatments for obesity and metabolic disorders. The U.S. FDA has recently given the green light for the Investigational New Drug Application (IND) for CIN-110, enabling the start of the first clinical trials in humans. The initial group of participants has already been given the drug in a study designed to assess the safety, tolerability, and various pharmacological aspects of CIN-110 in overweight individuals.
Dr. Jon Isaacsohn, CEO of CinRx Pharma, highlighted the ongoing need for well-tolerated, long-term obesity treatments and expressed optimism in CIN-110's potential to offer significant therapeutic benefits, both as a standalone treatment and in combination with other drugs. The compound is a stable analog of PYY3-36, which is a naturally occurring gut hormone that helps to suppress appetite by activating the neuropeptide Y2 receptor (Y2R). CIN-110 is designed to minimize severe nausea and vomiting, common side effects of similar treatments, while still promoting weight loss. Preclinical studies have shown that repeated dosing of CIN-110 significantly reduces food intake and body weight in obese animals, and it also improves glucose regulation and insulin sensitivity. Toxicology studies indicate that CIN-110 is well tolerated, with no adverse effects observed in animal models.
CinFina Pharma is expanding its pipeline with therapeutic candidates aimed at providing safe, tolerable, and long-lasting solutions to help individuals with obesity. The company's approach involves using naturally occurring peptides that are engineered to have a prolonged effect, targeting insulin secretion and satiety signals within the body. CinRx Pharma, the parent company, operates under a unique business model that accelerates the development of a diverse range of high-impact medicines, with a focus on areas of significant medical need, such as metabolism, gastrointestinal health, and oncology. CinRx identifies and funds promising drug candidates, leveraging strategic partnerships and insights from numerous development programs to enhance the potential impact on patients' lives.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!